11 January 2021: eXmoor Pharma, experts in strategic and technical biomanufacturing, specialising in cell and gene therapy, has signed a deal to work with the New Zealand Blood Service (NZBS).

Bristol-based eXmoor, which has worked in over 15 countries worldwide, will be providing NZBS with valuable Quality support as they build and establish a new site near Auckland.

The eXmoor UK team will be advising NZBS on the GMP (Good Manufacturing Practice) aspects of its proposed new build ATMP (advanced therapy medicinal products) facility based in Highbrook, New Zealand. They will provide GMP oversight over an initial four-month engagement with a view to longer term support.

This will be eXmoor’s first project in the Australasia region. The UK-based delivery team has adapted its working processes to allow for collaborative communication across time zones with the NZBS team.

 

This deal comes on the back of the work which eXmoor has undertaken in the UK for NHS Blood &Transplant (NHSBT) . 

eXmoor GMP Compliance Consultant, Rob Scott who will lead this project has provided QP services to NHSBT to release batches of product; the firm has worked with the Filton, Bristol-based Clinical Biotechnology Centre since 2017. 

Angela Osborne, CEO, eXmoor Pharma commented: “We are delighted to be working with NZBS. We have specific experience in supporting the manufacture of ATMPs having designed 32 manufacturing facilities and supported over 125 clients across more than 400 projects in the advanced therapies and biopharmaceutical sector.

“This facility is important to the future success and operation of NZBS and we are looking forward to building a long-term, collaborative relationship with their team.”

Fidelma Murphy, Director, Quality and Regulatory Affairs and Privacy Officer for New Zealand Blood Service, said: “I am pleased to be working with the eXmoor team. Their experience is unparalleled and the expertise and oversight they are providing will ensure the facility we develop and the way we operate for many years to come.”

This latest contract win for eXmoor comes off the back of the major £12m investment the firm announced earlier this year from healthcare investment firm MVM.  It is currently working towards expansion into the North American market and will also be opening its own dedicated 50,000 ft² CGT process development and clinical manufacturing facility in Bristol (UK) in 2022.